Tibet Rhodiola Pharmaceutical Holding Co.

SHSE:600211 Stock Report

Market Cap: CN¥12.0b

Tibet Rhodiola Pharmaceutical Holding Balance Sheet Health

Financial Health criteria checks 5/6

Tibet Rhodiola Pharmaceutical Holding has a total shareholder equity of CN¥3.7B and total debt of CN¥528.3M, which brings its debt-to-equity ratio to 14.4%. Its total assets and total liabilities are CN¥4.7B and CN¥1.0B respectively. Tibet Rhodiola Pharmaceutical Holding's EBIT is CN¥949.3M making its interest coverage ratio -10.8. It has cash and short-term investments of CN¥2.6B.

Key information

14.4%

Debt to equity ratio

CN¥528.32m

Debt

Interest coverage ratio-10.8x
CashCN¥2.59b
EquityCN¥3.66b
Total liabilitiesCN¥1.01b
Total assetsCN¥4.67b

Recent financial health updates

Tibet Rhodiola Pharmaceutical Holding (SHSE:600211) Could Easily Take On More Debt

Sep 02
Tibet Rhodiola Pharmaceutical Holding (SHSE:600211) Could Easily Take On More Debt

Tibet Rhodiola Pharmaceutical Holding (SHSE:600211) Seems To Use Debt Rather Sparingly

May 21
Tibet Rhodiola Pharmaceutical Holding (SHSE:600211) Seems To Use Debt Rather Sparingly

Recent updates

Investors Holding Back On Tibet Rhodiola Pharmaceutical Holding Co. (SHSE:600211)

Nov 27
Investors Holding Back On Tibet Rhodiola Pharmaceutical Holding Co. (SHSE:600211)

At CN¥33.30, Is Tibet Rhodiola Pharmaceutical Holding Co. (SHSE:600211) Worth Looking At Closely?

Sep 25
At CN¥33.30, Is Tibet Rhodiola Pharmaceutical Holding Co. (SHSE:600211) Worth Looking At Closely?

Tibet Rhodiola Pharmaceutical Holding (SHSE:600211) Could Easily Take On More Debt

Sep 02
Tibet Rhodiola Pharmaceutical Holding (SHSE:600211) Could Easily Take On More Debt

Insufficient Growth At Tibet Rhodiola Pharmaceutical Holding Co. (SHSE:600211) Hampers Share Price

Jul 29
Insufficient Growth At Tibet Rhodiola Pharmaceutical Holding Co. (SHSE:600211) Hampers Share Price

Investors Shouldn't Overlook Tibet Rhodiola Pharmaceutical Holding's (SHSE:600211) Impressive Returns On Capital

Jul 12
Investors Shouldn't Overlook Tibet Rhodiola Pharmaceutical Holding's (SHSE:600211) Impressive Returns On Capital

Tibet Rhodiola Pharmaceutical Holding (SHSE:600211) Seems To Use Debt Rather Sparingly

May 21
Tibet Rhodiola Pharmaceutical Holding (SHSE:600211) Seems To Use Debt Rather Sparingly

Shareholders Will Be Pleased With The Quality of Tibet Rhodiola Pharmaceutical Holding's (SHSE:600211) Earnings

May 03
Shareholders Will Be Pleased With The Quality of Tibet Rhodiola Pharmaceutical Holding's (SHSE:600211) Earnings

Under The Bonnet, Tibet Rhodiola Pharmaceutical Holding's (SHSE:600211) Returns Look Impressive

Mar 22
Under The Bonnet, Tibet Rhodiola Pharmaceutical Holding's (SHSE:600211) Returns Look Impressive

Financial Position Analysis

Short Term Liabilities: 600211's short term assets (CN¥3.5B) exceed its short term liabilities (CN¥976.4M).

Long Term Liabilities: 600211's short term assets (CN¥3.5B) exceed its long term liabilities (CN¥30.9M).

Debt to Equity History and Analysis

Debt Level: 600211 has more cash than its total debt.

Reducing Debt: 600211's debt to equity ratio has increased from 0% to 14.4% over the past 5 years.

Debt Coverage: 600211's debt is well covered by operating cash flow (194.5%).

Interest Coverage: 600211 earns more interest than it pays, so coverage of interest payments is not a concern.

Balance Sheet

Discover healthy companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 02:15
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Tibet Rhodiola Pharmaceutical Holding Co. is covered by 6 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Weina JiangEverbright Securities Co. Ltd.
Wen Liang CuiFounder Securities Co., Ltd.
Zhouyu DengGuosen Securities Co., Ltd.